As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is hunting for new patients to maintain its crown as Europe’s most valuable company.
Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk CEO on US Tariffs, Weight-Loss Sales, Supply Chain
Novo Nordisk A/S Chief Executive Officer and President Lars Fruergaard Jorgensen discusses the potential impact of tariffs coming from Donald Trump's administration in the US, demand for weight-loss medication,
Wegovy sales double but Novo Nordisk sees slower sales growth in 2025
Wegovy maker Novo Nordisk on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly in line with market expectations as the pace of ferocious demand for its wildly popular obesity drug Wegovy eases somewhat.
Novo Nordisk Expects Slowing Sales Growth This Year
The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs.
Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen investor concerns that the company is losing its edge in the competitive obesity market to rival Eli Lilly.
Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns.
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Prescriptions for weight loss drugs are skyrocketing, especially among young women. Experts think they know why.
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
How Weight-Loss Drugs Can Upend a Marriage
When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...
Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...
Rolling Out3d
The dark side of weight loss drugs no one warns about
New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...
Half of Americans Support Weight-Loss Drugs Like Ozempic for Obesity, Poll
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Pharmacies require stricter weight-loss jab checks
Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.